Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorJOMAA, Emilie
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorDELYFER, Marie-Noelle
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorKOROBELNIK, Jean-Francois
ORCID: 0000-0002-4438-9535
IDREF: 028739272
dc.date.accessioned2023-02-16T08:33:31Z
dc.date.available2023-02-16T08:33:31Z
dc.date.issued2022-12-06
dc.identifier.issn1724-6016 (Electronic) 1120-6721 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/171969
dc.description.abstractEnPURPOSE: Macular edema can be observed in 20% of patients with retinitis pigmentosa (RP) and is often responsible of central vision impairment. Intraocular administration of corticosteroids (either triamcinolone or dexamethasone implant) has been found to be effective in that indication. We here describe the first report of a successful bilateral administration of fluocinolone acetonide implant in a patient with steroid-dependent macular edema associated to RP. METHODS: Case report. CASE REPORT: A 34-year female patient with RP was referred for a one-year bilateral persistent ME. She had been refractory either to topical or to general carbonic anhydrase inhibitors. Bilateral off-label administration of 0.7 mg dexamethasone implant (Ozurdex®, Allergan, CA) was therefore decided. Efficacy and tolerance were very good in both eyes. Still, every four-month injections were required to maintain the macula dry. Off-label use of 0.19 mg fluocinolone acetonide (FAc) implant (Iluvien®, Alimera Sciences, GA) was then proposed and injected, first, in the right eye and, two-years after, in the left eye. No recurrences of the edema were observed from then on, i.e., for 3 years in the right eye and for 1 year in the left eye. CONCLUSION: Intravitreal fluocinolone acetonide could represent a promising means in the therapeutic management of persistent steroid-dependent ME related to RP.
dc.language.isoENen_US
dc.title.enFluocinolone acetonide implant (Iluvien(R)) for macular edema associated with retinitis pigmentosa: A case report
dc.title.alternativeEur J Ophthalmolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1177/11206721221144141en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed36474351en_US
bordeaux.journalEuropean Journal of Ophthalmologyen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamLEHA_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03991772
hal.version1
hal.date.transferred2023-02-16T08:33:33Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=European%20Journal%20of%20Ophthalmology&rft.date=2022-12-06&rft.eissn=1724-6016%20(Electronic)%201120-6721%20(Linking)&rft.issn=1724-6016%20(Electronic)%201120-6721%20(Linking)&rft.au=JOMAA,%20Emilie&DELYFER,%20Marie-Noelle&KOROBELNIK,%20Jean-Francois&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée